Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore
about
Antibiotic treatment of animals infected with Borrelia burgdorferiIn vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection modelApplication of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionPharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancerAlternative strategies for proof-of-principle studies of antibacterial agentsImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchAntiviral activity of Bifidobacterium adolescentis SPM1605 against Coxsackievirus B3A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen designTwo-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinumMathematical model of plasmid-mediated resistance to ceftiofur in commensal enteric Escherichia coli of cattlePharmacokinetics of Ceftiofur Crystalline-Free Acid in Clinically Healthy Dogs (Canis lupus familiaris)Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Spirochete antigens persist near cartilage after murine Lyme borreliosis therapyHollow-Fiber Methodology for Pharmacokinetic/Pharmacodynamic Studies of Antimalarial CompoundsDynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment.Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection ModelsComparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.Continuous clindamycin infusion, an innovative approach to treating bone and joint infectionsAntimicrobial stewardship in daily practice: Managing an important resource.Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infectionsPopulation pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersOral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens.Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital.Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery.Correcting a Fundamental Flaw in the Paradigm for Antimicrobial Susceptibility TestingAttenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.Pharmacokinetics of clindamycin in pregnant women in the peripartum period.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.Ciprofloxacin dosage and emergence of resistance in human commensal bacteriaAntimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationBeyond Susceptible and Resistant, Part I: Treatment of Infections Due to Gram-Negative Organisms With Inducible β-LactamasesIndividualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensStaphylococcus aureus in continuous culture: a tool for the rational design of antibiotic treatment protocols
P2860
Q24650857-E68FCA30-F9E7-452A-98C8-7E8F8FBDD2FEQ24654780-26BA725C-C639-4D7E-97ED-F837A03866DDQ26753831-0332A6AD-BBF2-485D-848C-6EB58468A49CQ26825326-022A8EAE-5A0C-40D2-823B-03C2CDAE448DQ26850895-0BD50D5B-BBCF-477A-937A-339F70C2E80FQ27024682-AE7D57DF-BB08-4D49-8C74-15434C5BE83AQ27026206-6338B404-5130-47A1-BED9-D2D71401E1DAQ28476705-3B0C675A-7B8A-4332-90DC-19CE3656D927Q28478890-1BA864BE-DE7A-4DEF-B85B-4BFFB3DB9EB8Q28483752-5490EBFE-3603-4246-9073-FC3D0D640803Q28603087-8F1808B2-0B0B-4368-88B5-3A5AAE46E622Q30383012-E4290FAE-ACCE-45EB-A02B-07EFA2ADA4DDQ30395441-E86CC911-5A48-4D63-BD73-13B733656A88Q30411703-98ECF760-E4E7-4B3B-BF98-AF046270175FQ30519448-01624CC7-B604-40E9-9AD0-4CA1A9B96583Q30734075-9D14F869-9601-44E7-88A3-7286723E2CB8Q31029779-741A9203-6F2D-47B5-B989-5DF81D111127Q31143801-D4377426-0A33-44B2-91D7-8ACE77B1BCB2Q33508985-1CDEFC11-D5F5-4FB4-AE8E-4AD382CA105EQ33559008-480E4BE0-85D6-49AB-A5B8-E9F30ADE3F13Q33642866-22DACCFA-9EBB-434B-A007-F9A3EA2DCE76Q33676144-FB72963E-01B3-4A11-B5B5-62280277C751Q33676387-A1B5F0A1-D2DA-444B-81F2-83AF3E6AAC80Q33720333-4A01E908-D605-4D3C-9B38-88126710F6C4Q33742525-E1456D2A-5FCD-4B83-A1EC-A80770A57664Q33797920-F29BFB3E-F7D3-445E-8994-F8AEEAEB837AQ33817871-D90AC23E-A8A9-415B-AF68-8E3431C98445Q33826267-E614F237-DFAD-4688-88A5-86EDFCC6A712Q33826411-9C95619A-C8BC-4739-AED7-07ADDA76AD8EQ33876423-3AA135CA-D3F4-4DAC-91E2-DAF9587964A7Q34045319-8938F99C-0081-4191-8122-A7A4E3FA7E18Q34104262-F6D63BAE-7059-4705-9C1D-1D4D91217220Q34188814-0083C70D-19D8-47F9-B2B3-6D179EF44FF3Q34266074-D6663F8B-3563-4EF5-86DD-08B2455705D7Q34274190-D7042B21-D876-4857-ACB1-7EEC56A35632Q34297656-9287A7B3-3C65-4D53-A3E7-C88CD26DFC51Q34298988-3FD00CA3-8700-4BDF-A5D9-E00C4C06BBB0Q34309574-F2B1972F-EF44-40D7-9F0F-C3A5AC0D88EBQ34381321-E8994B42-736E-4FEE-BAB4-55E1A523D8E0Q34387384-4D0C05B9-54BF-4FD4-8AC6-A70AF0592863
P2860
Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore
description
im Januar 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2007
@uk
name
Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore
@en
Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore
@nl
type
label
Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore
@en
Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore
@nl
prefLabel
Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore
@en
Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore
@nl
P2093
P356
P1476
Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore
@en
P2093
Alan Forrest
Arnold Louie
Christopher M. Rubino
George L. Drusano
Paul G. Ambrose
Sujata M. Bhavnani
P356
10.1086/510079
P407
P577
2007-01-01T00:00:00Z